Please note that the contents in this webpage are current as of the date of the announcement and the information including but not limited to the product availability, specification, prices, contacts, are subject to change without prior notice.

• 2024.09.03

  • News Release

  Approval of Partial Change to the Indication of AMYViD®,a PET Imaging Agent for Detecting Beta Amyloid

• 2024.07.01

  • News Release

  Dr. Masato Murakami Appointed as President and Representative Director of PDRadiopharma（PeptiDream Inc.）

• 2024.07.01

  Announcement of New Management Structure

• 2024.05.22

  • News Release

  Announcement of listing on the NHI Drug Price Standard of AMYViD®, a PET Imaging Agent for Detecting Beta Amyloid

• 2023.12.22

  • News Release

  Approval of Partial Change to the Indication of MyoMIBG® -I 123 Injection for Cardiac Scintigraphy for Patients with Parkinson’s Disease and Dementia with Lewy Bodies

• 2023.12.22

  • News Release

  PeptiDream and LinqMed Announce Strategic Partnership for the Development and Commercialization of 64Cu-ATSM in Japan（PeptiDream Inc.）

• 2023.12.20

  • News Release

  Approval of Insurance Coverage of AMYViD®, a PET Imaging Agent for Detecting Beta Amyloid

• 2023.10.31

  • News Release

  Acquisition of Assets for Radiopharmaceutical Data Solutions

• 2023.08.31

  • News Release

  Approval of partial change to the indication of AMYViD®, a PET imaging agent for detecting beta amyloid

• 2022.09.29

  • Information

  The website of PDRadiopharma Inc. is now available in English.